• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- Mpox infections may outnumber diagnosed cases 33 to 1, study suggests

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
www.cidrap.umn.edu/mpox/mpox-infections-may-outnumber-diagnosed-cases-33-1-study-suggests

Mpox infections may outnumber diagnosed cases 33 to 1, study suggests



Laine Bergeson


38 minutes ago.

Mpox
Asymptomatic mpox infections among men who have sex with men (MSM) may be far more common than previously recognized and could be playing a role in ongoing transmission, according to a study published last week in Nature Communications. Researchers estimate that actual infections may outnumber diagnosed cases by 33 to one.

The findings challenge the assumption that most mpox cases are spread by people with symptoms.

1% had asymptomatic mpox


For the study, researchers led by teams at the University of California (UC) at Berkeley and Kaiser Permanente Southern California tested for mpox in MSM in Los Angeles during routine sexually transmitted infection (STI) screening from May to November 2024. Then they monitored the same group of MSM for clinically diagnosed mpox.

Among nearly 8,000 eligible participants, only 15 laboratory-confirmed mpox cases were identified through standard clinical testing. But when the team tested for mpox DNA in 1,190 specimens collected from the routine STI tests, they found infections in six men who never presented with mpox symptoms or received an mpox diagnosis.

“We used the specimens from routine testing for other sexually transmitted diseases to test for mpox and found roughly 1% of men had asymptomatic infections without knowing it,” lead study author Joseph A. Lewnard, PhD, associate professor of epidemiology at the UC Berkeley School of Public Health, said in a news release. “From the testing, we estimated that only about one in every 33 infections gets diagnosed,” meaning infections exceeded reported cases by a 33-fold margin.

Undiagnosed cases may drive 31% to 44% of spread


These cryptic infections likely contribute to under-the-radar mpox spread. The authors estimate that undiagnosed infections may account for at least 31% to 44% of all transmission events and, under “realistic modelling assumptions,” potentially much more.

The findings run counter to current guidance from the Centers for Disease Control and Prevention, which has advised that people with symptoms primarily drive mpox spread, despite a lack of connection to a symptomatic partner.

“We have not known how mpox is transmitted, and why the cases seem to have very few connections to other cases,” senior study author and Kaiser Permanente scientist Sara Y. Tartof, PhD, MPH, said in the news release. “These findings help resolve a fundamental question in the epidemiology of mpox by suggesting that infected people pose a risk of transmitting the disease to others even in the absence of clinical symptoms."

Vaccination may reduce disease severity


The researchers also found that pre-exposure immunization with the Jynneos vaccine was associated with 72% effectiveness against diagnosed mpox. The finding that previously vaccinated men accounted for five of the six subclinical infections identified through routine STI testing suggests that vaccination may help protect against mpox by reducing disease severity, which aligns with previous research.

“Unvaccinated people face risk of severe disease if they are exposed to mpox,” Lewnard said. “And our findings suggest this risk is greater than we previously understood.”
 
Back
Top Bottom